Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 3
1995 2
1996 3
1997 7
1998 3
1999 6
2000 7
2001 10
2002 10
2003 17
2004 15
2005 8
2006 11
2007 13
2008 8
2009 15
2010 14
2011 17
2012 17
2013 16
2014 15
2015 19
2016 27
2017 23
2018 16
2019 12
2020 20
2021 19
2022 13
2023 12
2024 19
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Results by year

Filters applied: . Clear all
Page 1
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Marty FM, et al. Among authors: boeckh m. N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6. N Engl J Med. 2017. PMID: 29211658 Free article. Clinical Trial.
BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. METHODS: In this phase 3, double-blind trial, we randomly assigned CMV-se …
BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Leterm …
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and MarrowTransplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Tomblyn M, et al. Among authors: boeckh mj. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238. doi: 10.1016/j.bbmt.2009.06.019. Biol Blood Marrow Transplant. 2009. PMID: 19747629 Free PMC article. No abstract available.
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN; CMV Definitions Working Group of the Transplant Associated Virus Infections Forum. Ljungman P, et al. Among authors: boeckh m. Clin Infect Dis. 2024 Sep 26;79(3):787-794. doi: 10.1093/cid/ciae321. Clin Infect Dis. 2024. PMID: 39041385 Free PMC article.
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most rec …
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose …
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. Bastidas A, et al. Among authors: boeckh mj. JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. JAMA. 2019. PMID: 31287523 Free PMC article. Clinical Trial.
IMPORTANCE: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. ...IN …
IMPORTANCE: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated …
Current and Future Strategies for the Prevention and Treatment of Cytomegalovirus Infections in Transplantation.
Heldman MR, Boeckh MJ, Limaye AP. Heldman MR, et al. Among authors: boeckh mj. Clin Infect Dis. 2025 Oct 6;81(3):581-592. doi: 10.1093/cid/ciae535. Clin Infect Dis. 2025. PMID: 39492698 Free PMC article. Review.
Successful prevention and treatment of cytomegalovirus (CMV) infection remains a central focus of clinical care in solid organ transplantation (SOT) and allogeneic hematopoietic cell transplantation (HCT). Over the past 5 years, pivotal clinical trials have created …
Successful prevention and treatment of cytomegalovirus (CMV) infection remains a central focus of clinical care in solid organ transplant …
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Ljungman P, et al. Among authors: boeckh m. Clin Infect Dis. 2017 Jan 1;64(1):87-91. doi: 10.1093/cid/ciw668. Epub 2016 Sep 28. Clin Infect Dis. 2017. PMID: 27682069
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most rec …
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose …
Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report.
Cheng GS, Crothers K, Aliberti S, Bergeron A, Boeckh M, Chien JW, Cilloniz C, Cohen K, Dean N, Dela Cruz CS, Dickson RP, Greninger AL, Hage CA, Hohl TM, Holland SM, Jones BE, Keane J, Metersky M, Miller R, Puel A, Ramirez J, Restrepo MI, Sheshadri A, Staitieh B, Tarrand J, Winthrop KL, Wunderink RG, Evans SE. Cheng GS, et al. Among authors: boeckh m. Ann Am Thorac Soc. 2023 Mar;20(3):341-353. doi: 10.1513/AnnalsATS.202212-1019ST. Ann Am Thorac Soc. 2023. PMID: 36856712 Free PMC article.
Millions of individuals live with compromised immunity because of cytotoxic cancer treatments, biological therapies, organ transplants, inherited and acquired immunodeficiencies, and other immune disorders. Despite broad awareness among clinicians that these patients are a …
Millions of individuals live with compromised immunity because of cytotoxic cancer treatments, biological therapies, organ transplants …
American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients.
Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, Lin A, Carpenter PA, Boeckh M, Papanicolaou GA, Dadwal SS, Chemaly RF. Khawaja F, et al. Among authors: boeckh m. Transplant Cell Ther. 2025 Oct;31(10):727-741. doi: 10.1016/j.jtct.2025.06.025. Epub 2025 Jun 26. Transplant Cell Ther. 2025. PMID: 40581305 Free article.
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with the society's Transplant Infectious Diseases Special Interest Group to update its previous infectious disease guidelines for the prevention and managemen …
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with the society's Tra …
American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation.
Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, Papanicolaou GA, Boeckh M, Marty FM. Hakki M, et al. Among authors: boeckh m. Transplant Cell Ther. 2021 Sep;27(9):707-719. doi: 10.1016/j.jtct.2021.05.001. Transplant Cell Ther. 2021. PMID: 34452721 Free article.
The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoieti …
The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant …
Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP. Singh N, et al. Among authors: boeckh m. JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138. JAMA. 2020. PMID: 32286644 Free PMC article. Clinical Trial.
OBJECTIVE: To compare preemptive therapy with antiviral prophylaxis in CMV-seronegative liver transplant recipients with seropositive donors for the prevention of CMV disease. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of preemptive therapy vs antiviral p …
OBJECTIVE: To compare preemptive therapy with antiviral prophylaxis in CMV-seronegative liver transplant recipients with seropositive …
362 results